(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/274974 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2022/067603

(22) International Filing Date:
27 June 2022 (27.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2109373.7	29 June 2021 (29.06.2021)	GB
2109375.2	29 June 2021 (29.06.2021)	GB
2109377.8	29 June 2021 (29.06.2021)	GB

(71) Applicants: **ADC THERAPEUTICS SA** [CH/CH]; Biopôle, Route de la Corniche 3B, 1066 Epalinges (CH). **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **VAN BERKEL, Patricius Hendrikus Cornelis**; c/o I-HUB, Imperial College White City Campus, 84 Wood Lane, London Greater London W12 0BZ (GB). **ZAMMARCHI, Francesca**; c/o I-HUB, Imperial College White City Campus, 84 Wood Lane, London Greater London W12 0BZ (GB).

(74) Agent: **FINNIE, Nicholas**; ADC Therapeutics, I-HUB, Imperial College White City Campus, 84 Wood Lane, London Greater London W12 0BZ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATES




Figure 1

(57) Abstract: The present disclosure relates to combinations of anti-CD19 antibody drug conjugates and anti-CD79b conjugates, and their use in therapy, such as treating proliferative disorders.

WO 2023/274974 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*